Visualization of dopaminergic midbrain structures in Parkinson’s disease

Cover Page


MRI morphometry of the substantia nigra (SN) and the red nucleus was performed in patients with Parkinson’s disease (PD) (1 and 3 stage by Hoehn and Yahr) and healthy individuals using modes T2 and T2*-WI on magnetic resonance system ”Initial Achieva 3.0T”. Nonsignificant volume decrease of SN was revealed in patients with early manifestations of PD, and vice versa, its increase in symptomatic PD, which can be regarded as an analogue of the well-known phenomenon of ultrasonography in PD. Significantly greater than in the control SN volume asymmetry was marked in PD patients, and asymmetry increased in the progression of the disease. The findings suggest the possibility of using MRI morphometry of the brainstem structures to assess the course of the neurodegenerative process in PD.


About the authors

R. R. Bogdanov

Moscow Regional Research and Clinical Institute named after M.F. Vladimirsky

Author for correspondence.
Russian Federation

E. I. Manannikova

Moscow Regional Research and Clinical Institute named after M.F. Vladimirsky

Russian Federation

A. S. Abramenko

Moscow Regional Research and Clinical Institute named after M.F. Vladimirsky

Russian Federation

T. V. Maratkanova

Moscow Regional Research and Clinical Institute named after M.F. Vladimirsky

Russian Federation

S. V. Kotov

Moscow Regional Research and Clinical Institute named after M.F. Vladimirsky

Russian Federation


  1. Богданов Р.Р., Богданов А.Р., Котов С.В. Тактика ведения пациентов с начальными проявлениями болезни Паркинсона. Доктор.Ру; 2012; 5 (73): 17–21.
  2. Иллариошкин С.Н. Течение болезни Паркинсона и подходы к ранней диагностике. В кн.: Болезнь Паркинсона и расстройства движений: Руководство для врачей по материалам II Нац. конгресса. М.: 2011; 41–47.
  3. Левин О.С., Федорова Н.В. Болезнь Паркинсона. М.:МЕДпресс, 2012.
  4. Левин О.С. Клиническая эпидемиология болезни Паркинсона. В кн.: Болезнь Паркинсона и расстройства движений. Руководство для врачей по материалам II Нац. конгресса. М., 2011; 5–9.
  5. Шток В.Н., Иванова-Смоленская И.А., Левин О.С. Экстрапирамидные расстройства. М.: МЕДпресс-информ, 2002.
  6. Behnke S., Double K.L., Duma S. et al. Substantia nigra echomorphology in the healthy very old: Correlation with motor slowing. Neuroimage. 2007; 34 (3): 1054–1059.
  7. Braak H., Del Tredici K., Rub U. et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging. 2003; 24 (2): 197–211.
  8. Braak H., Rub U., Jansen Steur E.N. et al. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology. 2005; 64 (8): 1404–1410.
  9. Brooks D.J. Imaging Approaches to Parkinson Disease. J. Nucl. Med. 2010; 51 (4): 596-609.
  10. Brüggemann N., Hagenah J., Stanley K. et al. Substantia nigra hyperechogenicity with LRRK2 G2019S mutations. Mov Disord. 2011; 26 (5): 885–888.
  11. Double K., Gerlach M., Schünemann V. et al. Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem. Pharmacol. 2003; 66 (3): 489–494.
  12. Eapen M., Zald D.H., Gatenby J.C. et al. Using High-Resolution MR Imaging at 7T to Evaluate the Anatomy of the Midbrain Dopaminergic System. AJNR Am. J. Neuroradiol. 2011; 32 (4): 688–694.
  13. Fahn S., Elton R. Unified parkinson’s disease rating scale // in Fahn
  14. S., C.D. Marsden, Caine D.B., Goldstein M. (Eds). Recent developments in Parkinson’s disease. NJ: Macmillan Health Care Information, Florham Park. 1987: Vol. 2, 153–163.
  15. Geng D.Y., Li Y.X., Zee C.S.Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson’s disease. Neurosurgery. 2006; 58 (2): 256–262.
  16. Gorell J.M., Ordidge R.J., Brown G.G. et al. Increased iron-related MRI contrast in the substantia nigra in Parkinson’s disease. Neurology. 1995; 45 (6): 1138–1143.
  17. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression, and mortality. Neurology. 1967; 17 (5): 427–442.
  18. Hughes A.J., Daniel S.E., Blankson S. et al. A clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol. 1993; 50 (2): 140–148.
  19. Jubault T., Brambati S.M., Degroot C. et al. Regional brain stem atrophy in idiopathic parkinson’s disease detected by anatomical MRI. PLoS ONE. 2009; 4 (12): e8247.
  20. Kashihara K., Shinya T., Higaki F. Reduction of neuromelaninpositive nigral volume in patients with MSA, PSP and CBD. Intern. Med. 2011; 50 (16): 1683–1687.
  21. Manova E.S., Habib C.A., Boikov A.S. et al. Characterizing the mesencephalon using susceptibility-weighted imaging. AJNR Am. J. Neuroradiol. 2009; 30 (3): 569–574.
  22. McKeown M.J., Uthama A., Abugharbieh R. et al. Shape (but not volume) changes in the thalami in Parkinson disease. BMC Neurol. 2008; doi: 10.1186/1471-2377-8-8.
  23. Menke R.A., Scholz J., Miller K.L. et al. MRI characteristics of the substantia nigra in Parkinson’s disease: a combined quantitative T1 and DTI study. Neuroimage. 2009; 47 (2): 435–441.
  24. Minati L., Grisoli M., Carella F. et al. Imaging degeneration of the substantia nigra in Parkinson disease with inversion-recovery MR imaging. AJNR Am. J. Neuroradiol. 2007; 28 (2): 309–313.
  25. Naidich T.P., Duvernoy H.M., Delman B.N. et al. Duvernoy’s atlas of the human drain stem and cerebellum. Wien: Springer-Verlag, 2009: 53–116.
  26. Oikawa H., Sasaki M., Tamakawa Y. et al. The substantia nigra in Parkinson disease: proton density-weighted spin-echo and fast short inversion time inversion-recovery MR findings. AJNR Am. J. Neuroradiol. 2002; 23 (10): 1747–1756.
  27. Ordidge R.J., Gorell J.M., Deniau J.C. et al. Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla. Magn. Reson. Med. 1994; 32 (3): 335–341.
  28. Sasaki M., Shibata E., Tohyama K. et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson’s disease. Neuroreport. 2006; V. 17 (11): 1215–1218.
  29. Schneider S.A., Edwards M.J., Mir P. et al. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord. 2007; 22 (15): 2210–2215.
  30. Stoessl A.J. Neuroimaging in Parkinson’s disease. Neurotherapeutics. 2011; 8 (1): 72–81.
  31. Tessa C., Giannelli M., Della Nave R. et al. A whole-brain analysis in de novo parkinson disease. AJNR Am. J. Neuroradiol. 2008; 29 (4): 674–680.
  32. Vaillancourt D.E., Spraker M.B., Prodoehl J. et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology. 2009; 72 (16): 1378–1384.
  33. Whone A.L., Watts R.L., Stoessl J. et al. Slower progression of PD with ropinirole versus L-dopa: the REAL-PET study. Ann. Neurol. 2003; 54 (1): 93–101.
  34. Zecca L., Gallorini M., Schuenemann V. et al. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 2001; 76 (6): 1766–1773.



Abstract: 735

PDF (Russian): 508

Article Metrics

Metrics Loading ...



Copyright (c) 2017 Bogdanov R.R., Manannikova E.I., Abramenko A.S., Maratkanova T.V., Kotov S.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies